186 related articles for article (PubMed ID: 21642893)
1. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
Wen Y; Gorsic LK; Wheeler HE; Ziliak DM; Huang RS; Dolan ME
Pharmacogenet Genomics; 2011 Aug; 21(8):476-88. PubMed ID: 21642893
[TBL] [Abstract][Full Text] [Related]
2. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.
Stark AL; Hause RJ; Gorsic LK; Antao NN; Wong SS; Chung SH; Gill DF; Im HK; Myers JL; White KP; Jones RB; Dolan ME
PLoS Genet; 2014 Apr; 10(4):e1004192. PubMed ID: 24699359
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans.
Wheeler HE; Gorsic LK; Welsh M; Stark AL; Gamazon ER; Cox NJ; Dolan ME
PLoS One; 2011; 6(7):e21920. PubMed ID: 21755009
[TBL] [Abstract][Full Text] [Related]
4. Copy number polymorphisms and anticancer pharmacogenomics.
Gamazon ER; Huang RS; Dolan ME; Cox NJ
Genome Biol; 2011; 12(5):R46. PubMed ID: 21609475
[TBL] [Abstract][Full Text] [Related]
5. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
O'Donnell PH; Gamazon E; Zhang W; Stark AL; Kistner-Griffin EO; Stephanie Huang R; Eileen Dolan M
Pharmacogenet Genomics; 2010 May; 20(5):327-37. PubMed ID: 20393316
[TBL] [Abstract][Full Text] [Related]
6. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
[TBL] [Abstract][Full Text] [Related]
7. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
Nguyen DM; Yeow WS; Ziauddin MF; Baras A; Tsai W; Reddy RM; Chua A; Cole GW; Schrump DS
Cancer J; 2006; 12(4):257-73. PubMed ID: 16925970
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide.
Marklund L; Henriksson R; Grankvist K
Int J Cancer; 2001 Aug; 93(4):577-83. PubMed ID: 11477563
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis.
Shukla SJ; Duan S; Badner JA; Wu X; Dolan ME
Pharmacogenet Genomics; 2008 Mar; 18(3):253-62. PubMed ID: 18300947
[TBL] [Abstract][Full Text] [Related]
11. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.
Stark AL; Zhang W; Mi S; Duan S; O'Donnell PH; Huang RS; Dolan ME
Pharmacogenomics J; 2010 Dec; 10(6):505-12. PubMed ID: 20142840
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
Hsu DS; Balakumaran BS; Acharya CR; Vlahovic V; Walters KS; Garman K; Anders C; Riedel RF; Lancaster J; Harpole D; Dressman HK; Nevins JR; Febbo PG; Potti A
J Clin Oncol; 2007 Oct; 25(28):4350-7. PubMed ID: 17906199
[TBL] [Abstract][Full Text] [Related]
13. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.
Li R; Kim D; Wheeler HE; Dudek SM; Dolan ME; Ritchie MD
Pharmacogenomics J; 2019 Apr; 19(2):178-190. PubMed ID: 29795408
[TBL] [Abstract][Full Text] [Related]
14. Role of GADD34 in modulation of cisplatin cytotoxicity.
Fishel ML; Rabik CA; Bleibel WK; Li X; Moschel RC; Dolan ME
Biochem Pharmacol; 2006 Jan; 71(3):239-47. PubMed ID: 16325149
[TBL] [Abstract][Full Text] [Related]
15. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.
Wen Y; Gamazon ER; Bleibel WK; Wing C; Mi S; McIlwee BE; Delaney SM; Duan S; Im HK; Dolan ME
Hum Mol Genet; 2012 Apr; 21(7):1470-80. PubMed ID: 22171072
[TBL] [Abstract][Full Text] [Related]
16. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity.
Stark AL; Delaney SM; Wheeler HE; Im HK; Dolan ME
Hum Mol Genet; 2012 Oct; 21(19):4348-55. PubMed ID: 22773733
[TBL] [Abstract][Full Text] [Related]
17. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
19. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
20. Whole-genome approach implicates CD44 in cellular resistance to carboplatin.
Shukla SJ; Duan S; Wu X; Badner JA; Kasza K; Dolan ME
Hum Genomics; 2009 Jan; 3(2):128-42. PubMed ID: 19164090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
